EuBiologics Reports No Severe Adverse Events in Phase 1 Shingles Vaccine Main Study

• EuBiologics disclosed completed Phase 1 results for its EuHZV shingles vaccine, receiving the final clinical study report on September 23, 2026.
• No severe or life-threatening adverse events occurred during the main study; no adverse events led to dosing interruptions or discontinuations.
• A serious adverse event during follow-up was deemed unrelated to vaccination.
• A planned Phase 2 trial will further assess the selected dose’s safety and immune response in a larger population.
• Commercialization rights belong to 80%-owned EuPOP Life Sciences; negotiations to secure domestic rights remain ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EuBiologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021900651), on October 21, 2026, and is solely responsible for the information contained therein.